Emerging treatments in the management of tuberous sclerosis complex

Pediatric Neurology

Volumn 46, Issue 5, 2012, Pages 267-275

  Kohrman, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; TUBERIN;

ACNE; ACNEIFORM DERMATITIS; ANGIOMYOLIPOMA; ARTIFICIAL EMBOLISM; ASTROCYTOMA; BRAIN VENTRICLE DILATATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DERMATITIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG TOLERABILITY; GENE; GENE MUTATION; GIANT CELL TUMOR; HAMARTOMA; HUMAN; HYPERTRIGLYCERIDEMIA; LYMPHANGIOLEIOMYOMATOSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; STOMATITIS; SUBEPENDYMOMA; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX 1 GENE; TUBEROUS SCLEROSIS COMPLEX 2 GENE;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; SIGNAL TRANSDUCTION; SIROLIMUS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84859927489     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2012.02.015     Document Type: Review

References (68)

1. F.E. Jansen, O. van Nieuwenhuizen, and A.C. van Huffelen Tuberous sclerosis complex and its founders J Neurol Neurosurg Psychiatry 75 2004 770 (Pubitemid 38526692)
2. H.J. Baskin Jr. The pathogenesis and imaging of the tuberous sclerosis complex Pediatr Radiol 38 2008 936 952
3. P. Curatolo, R. Bombardieri, and S. Jozwiak Tuberous sclerosis Lancet 372 2008 657 668
4. G.L. Holmes, and C.E. Stafstrom Tuberous sclerosis complex and epilepsy: Recent developments and future challenges Epilepsia 48 2007 617 630 (Pubitemid 46587608)
5. P.B. Crino, K.L. Nathanson, and E.P. Henske The tuberous sclerosis complex N Engl J Med 355 2006 1345 1356
6. E.S. Roach, M.R. Gomez, and H. Northrup Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria J Child Neurol 13 1998 624 628 (Pubitemid 29035481)
7. F.J. DiMario Jr. Brain abnormalities in tuberous sclerosis complex J Child Neurol 19 2004 650 657
8. D.N. Franz, J.J. Bissler, and F.X. McCormack Tuberous sclerosis complex: Neurological, renal, and pulmonary manifestations Neuropediatrics 41 2010 199 208
9. M. Wong Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation Epilepsia 49 2008 8 21
10. P.F. Bolton, R.J. Park, J.N. Higgins, P.D. Griffiths, and A. Pickles Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex Brain 125 2002 1247 1255 (Pubitemid 34587134)
11. P.J. de Vries Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex Neurotherapeutics 7 2010 275 282
12. M.L. Krishnan, O. Commowick, and S.S. Jeste Diffusion features of white matter in tuberous sclerosis with tractography Pediatr Neurol 42 2010 101 106
13. K.A. Orlova, and P.B. Crino The tuberous sclerosis complex Ann NY Acad Sci 1184 2010 87 105
14. S.K. Rakowski, E.B. Winterkorn, E. Paul, D.J. Steele, E.F. Halpern, and E.A. Thiele Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors Kidney Int 70 2006 1777 1782 (Pubitemid 44684809)
15. L. Longa, F. Scolari, and A. Brusco A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease Nephrol Dial Transplant 12 1997 1900 1907 (Pubitemid 27379463)
16. A. Boletta Emerging evidence of a link between the polycystins and the mTOR pathways Pathogenetics 2 2009 6
17. E.P. Henske Tuberous sclerosis and the kidney: From mesenchyme to epithelium, and beyond Pediatr Nephrol 20 2005 854 857 (Pubitemid 40909251)
18. D.N. Franz, A. Brody, and C. Meyer Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis Am J Respir Crit Care Med 164 2001 661 668 (Pubitemid 32801674)
19. J.J. Yu, V.A. Robb, and T.A. Morrison Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells Proc Natl Acad Sci USA 106 2009 2635 2640
20. F.X. McCormack, Y. Inoue, and J. Moss Efficacy and safety of sirolimus in lymphangioleiomyomatosis N Engl J Med 364 2011 1595 1606
21. D.N. Franz Non-neurologic manifestations of tuberous sclerosis complex J Child Neurol 19 2004 690 698 (Pubitemid 39530079)
22. J. Borkowska, R.A. Schwartz, K. Kotulska, and S. Jozwiak Tuberous sclerosis complex: Tumors and tumorigenesis Int J Dermatol 50 2011 13 20
23. A.N. Datta, C.D. Hahn, and M. Sahin Clinical presentation and diagnosis of tuberous sclerosis complex in infancy J Child Neurol 23 2008 268 273 (Pubitemid 351247618)
24. C.P. Nelson, and M.G. Sanda Contemporary diagnosis and management of renal angiomyolipoma J Urol 168 2002 1315 1325 (Pubitemid 35034114)
25. A.E. Fryer, A. Chalmers, and J.M. Connor Evidence that the gene for tuberous sclerosis is on chromosome 9 Lancet 1 1987 659 661
26. R.S. Kandt, J.L. Haines, and M. Smith Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease Nat Genet 2 1992 37 41
27. European Chromosome 16 Tuberous Sclerosis Consortium Identification and characterization of the tuberous sclerosis gene on chromosome 16 Cell 75 1993 1305 1315
28. M. van Slegtenhorst, R. de Hoogt, and C. Hermans Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 Science 277 1997 805 808 (Pubitemid 27366729)
29. K.S. Au, A.T. Williams, M.J. Gambello, and H. Northrup Molecular genetic basis of tuberous sclerosis complex: From bench to bedside J Child Neurol 19 2004 699 709 (Pubitemid 39530080)
30. V. Napolioni, R. Moavero, and P. Curatolo Recent advances in neurobiology of tuberous sclerosis complex Brain Dev 31 2009 104 113
31. O. Sancak, M. Nellist, and M. Goedbloed Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex Eur J Hum Genet 13 2005 731 741 (Pubitemid 40846845)
32. G.M. Jentarra, S.G. Rice, S. Olfers, D. Saffen, and V. Narayanan Evidence for population variation in TSC1 and TSC2 gene expression BMC Med Genet 12 2011 29
33. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945 (Pubitemid 39071573)
34. J. Brugarolas, K. Lei, and R.L. Hurley Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Genes Dev 18 2004 2893 2904 (Pubitemid 39602308)
35. D.J. Kwiatkowski, and B.D. Manning Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways Hum Mol Genet 14 2005 R251 R258 (Pubitemid 41631882)
36. X. Wang, and C.G. Proud The mTOR pathway in the control of protein synthesis Physiology 21 2006 362 369 (Pubitemid 44511764)
37. L.W. Ellisen Growth control under stress: mTOR regulation through the REDD1-TSC pathway Cell Cycle 4 2005 1500 1502
38. J. Huang, and B.D. Manning The TSC1-TSC2 complex: A molecular switchboard controlling cell growth Biochem J 412 2008 179 190 (Pubitemid 351758225)
39. J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, and P.A. Dennis Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations Drug Resist Update 11 2008 32 50
40. L. Swiech, M. Perycz, A. Malik, and J. Jaworski Role of mTOR in physiology and pathology of the nervous system Biochim Biophys Acta 1784 2008 116 132
41. P.J. de Vries, and C.J. Howe The tuberous sclerosis complex proteins: A GRIPP on cognition and neurodevelopment Trends Mol Med 13 2007 319 326 (Pubitemid 47126986)
42. J.A. Chan, and H. Zang Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation J Neuropathol Exp Neurol 63 2004 1236 1242 (Pubitemid 39603395)
43. R. Moavero, C. Cerminara, and P. Curatolo Epilepsy secondary to tuberous sclerosis: Lessons learned and current challenges Childs Nerv Syst 26 2010 1495 1504
44. J.R. Sampson Therapeutic targeting of mTOR in tuberous sclerosis Biochem Soc Trans 37 2009 259 264
45. N. Chapuis, J. Tamburini, and A.S. Green Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies Leukemia 24 2010 1686 1699
46. G. Hess, R. Herbrecht, and J. Romaguera Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829
47. S. Gabardi, and S.A. Baroletti Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology Pharmacotherapy 30 2010 1044 1056
48. D.A. Krueger, M.M. Care, and K. Holland Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
49. R. Nabbout, M. Santos, Y. Rolland, O. Delalande, O. Dulac, and C. Chiron Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis J Neurol Neurosurg Psychiatry 66 1999 370 375 (Pubitemid 29103492)
50. J.J. Bissler, F.X. McCormack, and L.R. Young Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N Engl J Med 358 2008 140 151
51. ClinicalTrials.gov. www.clinicaltrials.gov. Accessed February 2, 2012.
52. D.N. Franz, J. Leonard, and C. Tudor Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann Neurol 59 2006 490 498 (Pubitemid 43358069)
53. M.K. Koenig, I.J. Butler, and H. Northrup Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex J Child Neurol 23 2008 1238 1239
54. A. Birca, C. Mercier, and P. Major Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex J Neurosurg Pediatr 6 2010 381 384
55. C. Lam, E. Bouffet, U. Tabori, D. Mabbott, M. Taylor, and U. Bartels Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors Pediatr Blood Cancer 54 2010 476 479
56. J. Jozwiak, S. Jozwiak, and M. Oldak Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment Med Res Rev 26 2006 160 180 (Pubitemid 43334640)
57. M. Yalon, L. Ben-Sira, S. Constantini, and A. Toren Regression of subependymal giant cell astrocytomas with RAD001 (everolimus) in tuberous sclerosis complex Childs Nerv Syst 27 2011 179 181
58. ® (everolimus) tablets for oral administration [prescribing information] 2011 Novartis Pharmaceuticals Corporation East Hanover, NJ
59. M. Wong Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies Epilepsia 51 2010 27 36
60. D. Ehninger, P.J. de Vries, and A.J. Silva From mTOR to cognition: Molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis J Intellect Disabil Res 53 2009 838 851
61. D. Ehninger, and A.J. Silva Rapamycin for treating tuberous sclerosis and autism spectrum disorders Trends Mol Med 17 2011 78 87
62. +/- mouse model of tuberous sclerosis Nat Med 14 2008 843 848
63. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann Neurol 63 2008 444 453 (Pubitemid 351614710)
64. P. Sooriakumaran, P. Gibbs, and G. Coughlin Angiomyolipomata: Challenges, solutions, and future prospects based on over 100 cases treated BJU Int 105 2010 101 106
65. D.H. Ewalt, N. Diamond, and C. Rees Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex J Urol 174 2005 1764 1766 (Pubitemid 41546930)
66. R. Wienecke, I. Fackler, U. Linsenmaier, K. Mayer, T. Licht, and M. Kretzler Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex Am J Kidney Dis 48 2006 e27 e29 (Pubitemid 44262422)
67. R. Peces, C. Peces, and E. Cuesta-Lopez Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex Nephrol Dial Transplant 25 2010 3787 3791
68. L. Krischock, R. Beach, and J. Taylor Sirolimus and tuberous sclerosis-associated renal angiomyolipomas Arch Dis Child 95 2010 391 392